Skeletal Muscle Differentiation kit now with control myoblasts

The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation.

Now available with the option of simple to use control myoblasts, stem cell researchers looking to differentiate stem cells to skeletal muscle with multinucleated myotubes can produce consistent, high-quality results every time. Methods for studying muscular disease and potential therapies were, until recently, dependent on invasive muscle biopsies to produce limited batches of primary cells. Traditional use of primary cells presented challenges, not only in the collection process but also related to inconsistencies in cell growth, behavior and life span, making it difficult to generate dependable experimental models.

Using the innovative AMSBIO Skeletal Muscle Differentiation kit allows researchers to generate muscle from human pluripotent stem cells in three easy steps, via satellite-like or progenitor cells and myoblasts that then fuse to multinucleated myotubes in the third step.

Removing the need for time consuming cell sorting or transfection of myogenic transcription factors, the Skeletal Muscle Differentiation kit protocol generates a highly pure population of approximately 70 per cent skeletal muscle myotubes in a reproducible fashion. This kit has been proven on a wide range of embryonic and induced pluripotent stem cell (ESC and iPSC) lines. 

For further information please visit or contact AMSBIO now on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 /   

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.


Worldwide HQ

AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE

Tel: +44-1235-828200
Fax: +44-1235-820482


North American HQ

1035 Cambridge Street
MA 02141

Tel:      +1.617.945.5033
Tel:      +1.800.987.0985 (toll free)

Media Contact Information: 

Dr Bill Bradbury